Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Diuretic Effects of Sodium Glucose Cotransporter 2 Inhibitors and Their Influence on the Renin-Angiotensin System
Tuba M. Ansary, Daisuke Nakano, Akira Nishiyama
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 3, pp. 629-629
Open Access | Times Cited: 146

Showing 1-25 of 146 citing articles:

Sodium–glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus
André Scheen
Nature Reviews Endocrinology (2020) Vol. 16, Iss. 10, pp. 556-577
Closed Access | Times Cited: 228
Effect of SGLT2 inhibitors on body composition, fluid status and renin–angiotensin–aldosterone system in type 2 diabetes: a prospective study using bioimpedance spectroscopy
Anja Schork, Janine Saynisch, Andreas Vosseler, et al.
Cardiovascular Diabetology (2019) Vol. 18, Iss. 1
Open Access | Times Cited: 189
Obesity and the kidney: mechanistic links and therapeutic advances
Kevin Yau, Rachel Kuah, David Z.I. Cherney, et al.
Nature Reviews Endocrinology (2024) Vol. 20, Iss. 6, pp. 321-335
Closed Access | Times Cited: 31
Effect of SGLT2 Inhibitors on the Sympathetic Nervous System and Blood Pressure
André Scheen
Current Cardiology Reports (2019) Vol. 21, Iss. 8
Closed Access | Times Cited: 105
Osmotic diuresis by SGLT2 inhibition stimulates vasopressin‐induced water reabsorption to maintain body fluid volume
Takahiro Masuda, Shigeaki Muto, Keiko Fukuda, et al.
Physiological Reports (2020) Vol. 8, Iss. 2
Open Access | Times Cited: 101
Sodium-coupled glucose transport, the SLC5 family, and therapeutically relevant inhibitors: from molecular discovery to clinical application
Gergely Gyimesi, Jonai Pujol‐Giménez, Yoshikatsu Kanai, et al.
Pflügers Archiv - European Journal of Physiology (2020) Vol. 472, Iss. 9, pp. 1177-1206
Open Access | Times Cited: 88
Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Renin-Angiotensin-Aldosterone System
Soraya Puglisi, Alessandro Rossini, Roberta Poli, et al.
Frontiers in Endocrinology (2021) Vol. 12
Open Access | Times Cited: 85
Cardiorenal protection with SGLT2 inhibitors in patients with diabetes mellitus: from biomarkers to clinical outcomes in heart failure and diabetic kidney disease
Hongyan Liu, Vikas S. Sridhar, Jacinthe Boulet, et al.
Metabolism (2021) Vol. 126, pp. 154918-154918
Closed Access | Times Cited: 63
Renoprotective mechanisms of sodium‐glucose co‐transporter 2 (SGLT2) inhibitors against the progression of diabetic kidney disease
Sreenithya Ravindran, Shankar Munusamy
Journal of Cellular Physiology (2021) Vol. 237, Iss. 2, pp. 1182-1205
Closed Access | Times Cited: 61
Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Water and Sodium Metabolism
Jun Tang, Lifang Ye, Qiqi Yan, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 58
SGLT2 Inhibitors as Potential Anticancer Agents
Debasish Basak, David Gamez, Subrata Deb
Biomedicines (2023) Vol. 11, Iss. 7, pp. 1867-1867
Open Access | Times Cited: 37
Mechanisms of SGLT2 Inhibitors in Heart Failure and Their Clinical Value
Yafei Xie, Yujie Wei, Dan Li, et al.
Journal of Cardiovascular Pharmacology (2023) Vol. 81, Iss. 1, pp. 4-14
Closed Access | Times Cited: 33
Nephrotic Syndrome: From Pathophysiology to Novel Therapeutic Approaches
Georgiana Frățilă, Gabriela Elena Lupusoru, Bogdan Sorohan, et al.
Biomedicines (2024) Vol. 12, Iss. 3, pp. 569-569
Open Access | Times Cited: 8
Canagliflozin for Japanese patients with chronic heart failure and type II diabetes
Akira Sezai, Hisakuni Sekino, Satoshi Unosawa, et al.
Cardiovascular Diabetology (2019) Vol. 18, Iss. 1
Open Access | Times Cited: 72
Molecular Mechanisms of SGLT2 Inhibitor on Cardiorenal Protection
Yi‐Chou Hou, Cai‐Mei Zheng, Tzung‐Hai Yen, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 21, pp. 7833-7833
Open Access | Times Cited: 68
Control of 24-hour blood pressure with SGLT2 inhibitors to prevent cardiovascular disease
Kazuomi Kario, Keith C. Ferdinand, James H. O’Keefe
Progress in Cardiovascular Diseases (2020) Vol. 63, Iss. 3, pp. 249-262
Open Access | Times Cited: 58
Renal physiology of glucose handling and therapeutic implications
David Z.I. Cherney, Mehmet Kanbay, Julie A. Lovshin
Nephrology Dialysis Transplantation (2019) Vol. 35, Iss. Supplement_1, pp. i3-i12
Open Access | Times Cited: 55
The extracellular volume status predicts body fluid response to SGLT2 inhibitor dapagliflozin in diabetic kidney disease
Ken Ohara, Takahiro Masuda, Masato Morinari, et al.
Diabetology & Metabolic Syndrome (2020) Vol. 12, Iss. 1
Open Access | Times Cited: 52
Direct Blood Pressure-Independent Anti-Fibrotic Effects by the Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone in Progressive Models of Kidney Fibrosis
Karoline Droebner, Mira Pavkovic, Manuel Grundmann, et al.
American Journal of Nephrology (2021) Vol. 52, Iss. 7, pp. 588-601
Open Access | Times Cited: 46
Sodium–glucose cotransporter 2 inhibitors and risk of nephrolithiasis
Kasper Bruun Kristensen, Daniel Pilsgaard Henriksen, Jesper Hallas, et al.
Diabetologia (2021) Vol. 64, Iss. 7, pp. 1563-1571
Open Access | Times Cited: 44
Effects of GLP-1 receptor agonists and SGLT-2 inhibitors on cardiac structure and function: a narrative review of clinical evidence
Andrea Natali, Lorenzo Nesti, Domenico Tricò, et al.
Cardiovascular Diabetology (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 44
SGLT2 inhibition effect on salt-induced hypertension, RAAS, and Na+ transport in Dahl SS rats
Olha Kravtsova, Ruslan Bohovyk, Vladislav Levchenko, et al.
AJP Renal Physiology (2022) Vol. 322, Iss. 6, pp. F692-F707
Open Access | Times Cited: 34
SGLT2 Inhibition and Kidney Potassium Homeostasis
Biff F. Palmer, Deborah J. Clegg
Clinical Journal of the American Society of Nephrology (2023) Vol. 19, Iss. 3, pp. 399-405
Open Access | Times Cited: 18
Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors for recurrent nephrolithiasis among patients with pre-existing nephrolithiasis or gout: target trial emulation studies
Natalie McCormick, Chio Yokose, Na Lu, et al.
BMJ (2024), pp. e080035-e080035
Open Access | Times Cited: 6
Cardioprotection conferred by sodium-glucose cotransporter 2 inhibitors: a renal proximal tubule perspective
Danúbia Silva dos Santos, Juliano Z. Polidoro, Flávio A. Borges-Júnior, et al.
AJP Cell Physiology (2019) Vol. 318, Iss. 2, pp. C328-C336
Open Access | Times Cited: 46
Page 1 - Next Page

Scroll to top